MK-0773 manufacturers
- MK-0773
-
- $196.00 / 5mg
-
2025-09-22
- CAS:606101-58-0
- Min. Order:
- Purity: 99.14%
- Supply Ability: 10g
- MK-0773
-
- $0.00 / 1kg
-
2025-08-22
- CAS:606101-58-0
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 20 tons
- MK-0773
-
- $10.00 / 1kg
-
2024-03-08
- CAS:606101-58-0
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000kg
|
| | MK-0773 Basic information |
| Product Name: | MK-0773 | | Synonyms: | MK-0773;PF 05314882;PF05314882;PF-05314882;N-(3H-Imidazo[4,5-b]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide;MK0773;MK 0773;PF 05314882;PF-05314882;PF05314882;1H-Indeno[5,4-f]quinoline-7-carboxamide, 3-fluoro-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-N-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-1,4a,6a-trimethyl-2-oxo-, (4aS,4bS,6aS,7S,9aS,9bS,11aR)-;MK 0773,MK0773 | | CAS: | 606101-58-0 | | MF: | C27H34FN5O2 | | MW: | 479.59 | | EINECS: | | | Product Categories: | | | Mol File: | 606101-58-0.mol |  |
| | MK-0773 Chemical Properties |
| Boiling point | 754.2±60.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 33.33 mg/mL (69.50 mM; Need ultrasonic) | | form | Powder | | pka | 10.29±0.40(Predicted) | | color | Light yellow to yellow |
| | MK-0773 Usage And Synthesis |
| Uses | MK-0773 is a selective androgen receptor modulator designed to improve muscle function while minimizing effects on other tissues. Furthermore, MK-0773 is useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal | | in vivo | MK-0773 (6 and 80 mg/kg, s.c.) produces exposure-related stimulatory effects on cortical BFR and LBM in the OVX rat model. MK-0773 (5, 15, and 80 mg/kg, s.c.) increases seminal vesicle weights, and has reduced effects on the prostate. The partial agonism and tissue selectivity of MK-0773 does not translate into differential effects on lipid metabolism in OVX rats[1]. | | target | androgen receptor |
| | MK-0773 Preparation Products And Raw materials |
| Raw materials | 1H-Indeno[5,4-f]quinoline-7-carboxylic acid, 3-fluoro-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-triMethyl-2-oxo-, (4aS,4bS,6aS,7S,9aS,9bS,11aR)- |
|